The Austrian biotechnology company specializes in the discovery of virulent skin microbiome components and antigens of bacteria that cause skin diseases such as acne. The transaction adds a potential vaccine candidate against acne vulgaris to Sanofi's production line, a disease that affects millions of people worldwide. To date, there is no satisfactory treatment for acne that combines high efficacy and acceptable safety. Together with Sanofi, Origimm aims to bring about paradigm shifts in the treatment of skin diseases and many other microbiome-associated diseases and infections. The transaction is expected to close in December 2021. The Binder Grösswang team included lead partner Thomas Schirmer and attorney Mona Holzgruber (Corporate / M&A). Also advising from the IP Team were Ivo Rungg (Partner) and Hellmut Buchroithner (Counsel), from the Tax Team Clemens Willvonseder (Partner) and from the Regulatory Team Johannes Barbist (Partner) and Regina Kröll (Attorney). Squire Patton Boggs (US) LLP, Frankfurt with Rüdiger Herrmann and Jochen Eimer acted as transaction counsel for the sellers. The buyer was represented by Schönherr with Roman Perner and Michael Marschall.